Printer Friendly

Research and Markets: Anxiety Disorders - Viable Indication for Antipsychotics Companies.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/c7f775/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Viable Indication for Antipsychotics Companies" report to their offering.

Despite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergic-based treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and maintain market share is growing as the patent expiries of three major brands draws near.

Scope

* Analysis of key marketed brands and late-stage pipeline drugs.

* Anxiety disorders-specific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.

* Identification of future market events that are expected to affect anxiety disorders drug revenues.

* Analysis of patient potential, unmet needs and clinical trial design in anxiety disorder.

Highlights of this title

Atypical antipsychotics are expected to change the landscape of the future anxiety disorders market, with Seroquel XR set to benefit from first-to-market status upon approval in generalized anxiety disorder. Seroquel XR will be positioned as a second/third-line treatment for patients who have failed to respond to available antidepressants.

In view of the high co-morbidity between anxiety and depression, it remains in the interests of antidepressant manufacturers to maximize the patient potential of their products. However, with three key brands set to experience patent expiration over the forecast period (20082017), competition within the antidepressant drug classes will intensify.

The presence of neurokinin (NK) receptor antagonists and corticotrophin releasing factor (CRF) antagonists in the anxiety disorders pipeline have generated much interest among interviewed key opinion leaders. Datamonitor regards NK receptor antagonists as holding the greatest promise in the treatment of anxiety disorders.

Key reasons to purchase this title

* Understand the current anxiety disorder market dynamics and how they are expected to evolve out to 2017.

* Benchmark key late-stage pipeline anxiety disorder compounds against the current market leading brands.

* Understand unmet needs in the anxiety disorders market based on key opinion leader comments.

Key Topics Covered:

* EXECUTIVE SUMMARY

* PATIENT POTENTIAL

* MARKET OVERVIEW

* BRAND DYNAMICS

* PIPELINE OVERVIEW - R&D DYNAMICS AND APPROACH

* LATE-STAGE DRUG ANALYSIS AND FORECASTS

For more information visit http://www.researchandmarkets.com/research/c7f775/anxiety_disorders

Source: Datamonitor
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 19, 2008
Words:372
Previous Article:Research and Markets: Psychosis, Trauma and Dissociation: Emerging Perspectives on Severe Psychopathology.
Next Article:Research and Markets: Private Label Shopping Trends in Food and Non-Alcoholic Beverages.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters